Dahut W - Search Results

1

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G, et al. Bubley GJ, et al. Among authors: dahut w. J Clin Oncol. 1999 Nov;17(11):3461-7. doi: 10.1200/JCO.1999.17.11.3461. J Clin Oncol. 1999. PMID: 10550143

2

Taxanes in hormone-refractory prostate cancer.

Kang MH, Figg WD, Dahut W. Kang MH, et al. Among authors: dahut w. Cancer Pract. 1999 Sep-Oct;7(5):270-2. doi: 10.1046/j.1523-5394.1999.75005.x. Cancer Pract. 1999. PMID: 10687598 Review. No abstract available.

3

8:45-9:00. Using PET 18F-FDG, 11CO, and 15O-water for Monitoring Prostate Cancer During a Phase II Anti-angiogenic Drug Trial with Thalidomide.

Kurdziel K, Bacharach S, Carrasquillo J, Huebsch S, Whatley M, Sellers D, Steinberg S, Libutti S, Pluda J, Reed E, Dahut W, Figg W. Kurdziel K, et al. Among authors: dahut w. Clin Positron Imaging. 2000 Jul;3(4):144. doi: 10.1016/s1095-0397(00)00056-x. Clin Positron Imaging. 2000. PMID: 11150747

4

Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer.

Rudek MA, Figg WD, Dyer V, Dahut W, Turner ML, Steinberg SM, Liewehr DJ, Kohler DR, Pluda JM, Reed E. Rudek MA, et al. Among authors: dahut w. J Clin Oncol. 2001 Jan 15;19(2):584-92. doi: 10.1200/JCO.2001.19.2.584. J Clin Oncol. 2001. PMID: 11208854 Clinical Trial.

5

Reversible sideroblastic anemia associated with the tetracycline analogue COL-3.

Rudek MA, Horne M, Figg WD, Dahut W, Dyer V, Pluda JM, Reed E. Rudek MA, et al. Among authors: dahut w. Am J Hematol. 2001 May;67(1):51-3. doi: 10.1002/ajh.1076. Am J Hematol. 2001. PMID: 11279658 Free article.

6

Drug-induced lupus associated with COL-3: report of 3 cases.

Ghate JV, Turner ML, Rudek MA, Figg WD, Dahut W, Dyer V, Pluda JM, Reed E. Ghate JV, et al. Among authors: dahut w. Arch Dermatol. 2001 Apr;137(4):471-4. Arch Dermatol. 2001. PMID: 11295928 Clinical Trial.

7

Thalidomide neuropathy in patients treated for metastatic prostate cancer.

Molloy FM, Floeter MK, Syed NA, Sandbrink F, Culcea E, Steinberg SM, Dahut W, Pluda J, Kruger EA, Reed E, Figg WD. Molloy FM, et al. Among authors: dahut w. Muscle Nerve. 2001 Aug;24(8):1050-7. doi: 10.1002/mus.1109. Muscle Nerve. 2001. PMID: 11439380 Clinical Trial.

8

A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.

Figg WD, Dahut W, Duray P, Hamilton M, Tompkins A, Steinberg SM, Jones E, Premkumar A, Linehan WM, Floeter MK, Chen CC, Dixon S, Kohler DR, Krüger EA, Gubish E, Pluda JM, Reed E. Figg WD, et al. Among authors: dahut w. Clin Cancer Res. 2001 Jul;7(7):1888-93. Clin Cancer Res. 2001. PMID: 11448901 Clinical Trial.

9

Alendronate does not interfere with 99mTc-methylene diphosphonate bone scanning.

Carrasquillo JA, Whatley M, Dyer V, Figg WD, Dahut W. Carrasquillo JA, et al. Among authors: dahut w. J Nucl Med. 2001 Sep;42(9):1359-63. J Nucl Med. 2001. PMID: 11535725 Free article.

10

A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer.

Figg WD, Arlen P, Gulley J, Fernandez P, Noone M, Fedenko K, Hamilton M, Parker C, Kruger EA, Pluda J, Dahut WL. Figg WD, et al. Among authors: dahut wl. Semin Oncol. 2001 Aug;28(4 Suppl 15):62-6. doi: 10.1016/s0093-7754(01)90157-5. Semin Oncol. 2001. PMID: 11685731 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

252 results

Search Page